News

The diabetes drugs Ozempic and Wegovy have been linked to an increased risk of sudden vision loss and blindness due to a rare ...
A new study from Mass Eye and Ear suggests that people taking semaglutide, a drug sold as Ozempic and Wegovy, may have a ...
Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.
As weight loss jabs like Ozempic become ever more popular, doctors are growing increasingly concerned about their gnarly side ...
The longer weight loss GLP-1 drugs like Ozempic and Wegovy have been on the market, the more side effects people are ...
The specific condition was non-arteritic anterior ischemic optic neuropathy. "That can cause this sudden and permanent vision loss, usually in just one eye. Now, I should be clear this isn't total ...
The drug is now available for prescription in New Zealand but there are clouds to go along with the silver linings - such as ...
WHO is alerting health-care professionals and regulatory authorities to the risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with the use of semaglutide medicines—Ozempic, ...
At the 2-year, 3-year, and 4-year time points from the index date, those taking semaglutide had an increased risk for nonarteritic anterior ischemic optic neuropathy. HealthDay News — For patients ...
Nonarteritic anterior ischemic optic neuropathy (NAION) is a leading cause of sudden vision loss, primarily affecting middle-aged and elderly individuals. Its hallmark features are an acute unilateral ...
For individuals with type 2 diabetes (T2D), semaglutide is associated with a modestly increased risk for nonarteritic anterior ischemic optic neuropathy (NAION).